Looking back at earlier preliminary phase 1a data and found the data presented to be useful when comparing CHM results to other drugs in development
The below slide showed the comparison against current drugs in development - not sure how these have progressed but worth looking into.
CHM trial all dose levels complete (n=11) DCR 55%
This slide form more recent presentation compare against current approved treatments
Most of the comments to date have been around CHM1101 compared to current approved treatments with CHM1101 stacking up pretty well. I think it's important to note that CHM1101 also stacks up well when compared to other drugs in development.
Ann: New data for Phase 1A CLTX CAR T brain cancer clinical trial, page-69
-
- There are more pages in this discussion • 7 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add CHM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
1.8¢ |
Change
0.001(2.94%) |
Mkt cap ! $15.51M | |||
| Open | High | Low | Value | Volume |
| 1.9¢ | 1.9¢ | 1.8¢ | $1.453K | 78.14K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 6 | 3420109 | 1.7¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 1.8¢ | 152674 | 3 |
View Market Depth
| Last trade - 14.19pm 16/08/2024 (20 minute delay) ? |
| CHM (ASX) Chart |